Pivotal study results for finerenone (Kerendia) in heart failure with mildly reduced or preserved ejection fraction were published on January 1, 2024, in the New England Journal of Medicine. The FINEARTS-HF study evaluated the drug's efficacy and safety in this patient population.
Background
Finerenone (Kerendia) is a drug investigated for heart failure. This publication details findings from the FINEARTS-HF study, focusing on its use in patients with heart failure characterized by mildly reduced or preserved ejection fraction.
Trial design
The FINEARTS-HF study evaluated the efficacy and safety of finerenone in participants diagnosed with heart failure and left ventricular ejection fraction that is mildly reduced or preserved. The study aimed to assess the drug's impact on disease outcomes in this specific patient group.
What this means
The publication of the FINEARTS-HF study in the New England Journal of Medicine makes the detailed findings on finerenone available to clinicians and researchers. While specific outcome data are not provided in this summary, the publication signifies that the efficacy and safety profile of finerenone in heart failure with mildly reduced or preserved ejection fraction can now be critically reviewed by the medical community. This information is crucial for understanding the potential role of finerenone in managing this challenging condition.
Source
The information regarding the publication of the FINEARTS-HF study was sourced from PubMed. The article, titled 'Finerenone in Heart Failure with Mildly Reduced or Preserved Ejection Fraction', was published on January 1, 2024, and is accessible via pubmed.ncbi.nlm.nih.gov.